Venous Thromboembolism in Patients with Heart Failure

Curr Pharm Des. 2021 Aug 29. doi: 10.2174/1381612827666210830102419. Online ahead of print.ABSTRACTHeart failure (HF) and venous thromboembolism (VTE) are common clinical entities, closely inter-related, sharing multiple pathophysiological mechanisms. Their co-incidence is associated with further worsening of the prognosis of one another. Despite their frequent co-existence, important clinical questions still remain unanswered. The risk of VTE especially in chronic HF patients appears to vary widely in clinical studies, while the VTE-associated risk in HF pa-tients is still not well determined and cannot be accurately predicted. Although scientific guidelines recommend venous thromboprophylaxis in patients hospitalized with an acute HF syndrome, venous thromboprophylaxis has not been studied adequately in prospective trials in ambulatory HF patients. In the present review, we aimed to summarize the current knowledge on the epidemiology of VTE and HF, the risk prediction for VTE occurrence in HF patients, the impact on patient outcome, and the need for anticoagulation in certain HF subgroups to improve prognosis, while we sought to identify gaps in knowledge that need to be addressed in the future.PMID:34459379 | DOI:10.2174/1381612827666210830102419
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Source Type: research